Cargando…

Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy

PURPOSE: Immune checkpoint inhibitors have opened a new scenario in the treatment of cancer. These agents can elicit adverse events, which may affect different systems and organs, including the endocrine system. The aims of this study were to evaluate the impact of the anti-PD-1 molecules nivolumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubino, Rossella, Marini, Andrea, Roviello, Giandomenico, Presotto, Elena Margherita, Desideri, Isacco, Ciardetti, Isabella, Brugia, Marco, Pimpinelli, Nicola, Antonuzzo, Lorenzo, Mini, Enrico, Livi, Lorenzo, Maggi, Mario, Peri, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440282/
https://www.ncbi.nlm.nih.gov/pubmed/34036513
http://dx.doi.org/10.1007/s12020-021-02750-w
_version_ 1783752677615730688
author Rubino, Rossella
Marini, Andrea
Roviello, Giandomenico
Presotto, Elena Margherita
Desideri, Isacco
Ciardetti, Isabella
Brugia, Marco
Pimpinelli, Nicola
Antonuzzo, Lorenzo
Mini, Enrico
Livi, Lorenzo
Maggi, Mario
Peri, Alessandro
author_facet Rubino, Rossella
Marini, Andrea
Roviello, Giandomenico
Presotto, Elena Margherita
Desideri, Isacco
Ciardetti, Isabella
Brugia, Marco
Pimpinelli, Nicola
Antonuzzo, Lorenzo
Mini, Enrico
Livi, Lorenzo
Maggi, Mario
Peri, Alessandro
author_sort Rubino, Rossella
collection PubMed
description PURPOSE: Immune checkpoint inhibitors have opened a new scenario in the treatment of cancer. These agents can elicit adverse events, which may affect different systems and organs, including the endocrine system. The aims of this study were to evaluate the impact of the anti-PD-1 molecules nivolumab and pembrolizumab on endocrine toxicity and on patient outcome. METHODS: A retrospective and multicentre study was designed, which involved a total of 251 patients affected by different tumors (mostly non-small cell lung cancer, 68.92% and melanoma, 24.30%) and treated with the PD-1 inhibitors nivolumab (61.35%) or pembrolizumab (38.65%) for up to 60 months. Clinical and biochemical data were recorded until July 31, 2020. RESULTS: Endocrine toxicity occurred in 70 out of 251 patients (27.89%). It was mostly related to thyroid dysfunction and in 75% of cases occurred within 6 months from the beginning of therapy. A previous endocrine morbidity and female gender were predictors of endocrine toxicity. There was no association between endocrine dysfunction and patient outcome. However, when all toxicities (i.e., endocrine and non endocrine) were considered, a significant association with progression-free survival and overall survival was found. CONCLUSIONS: Thyroid alterations are frequently observed in cancer patients treated with anti PD-1 drugs, particularly in women and in the presence of a previous endocrinopathy. We suggest that regular thyroid assessment should be performed in these patients, especially in the first months of therapy. Finally, the onset of side effects, related to anti PD-1 agents, appears to be associated with a better outcome.
format Online
Article
Text
id pubmed-8440282
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-84402822021-09-29 Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy Rubino, Rossella Marini, Andrea Roviello, Giandomenico Presotto, Elena Margherita Desideri, Isacco Ciardetti, Isabella Brugia, Marco Pimpinelli, Nicola Antonuzzo, Lorenzo Mini, Enrico Livi, Lorenzo Maggi, Mario Peri, Alessandro Endocrine Original Article PURPOSE: Immune checkpoint inhibitors have opened a new scenario in the treatment of cancer. These agents can elicit adverse events, which may affect different systems and organs, including the endocrine system. The aims of this study were to evaluate the impact of the anti-PD-1 molecules nivolumab and pembrolizumab on endocrine toxicity and on patient outcome. METHODS: A retrospective and multicentre study was designed, which involved a total of 251 patients affected by different tumors (mostly non-small cell lung cancer, 68.92% and melanoma, 24.30%) and treated with the PD-1 inhibitors nivolumab (61.35%) or pembrolizumab (38.65%) for up to 60 months. Clinical and biochemical data were recorded until July 31, 2020. RESULTS: Endocrine toxicity occurred in 70 out of 251 patients (27.89%). It was mostly related to thyroid dysfunction and in 75% of cases occurred within 6 months from the beginning of therapy. A previous endocrine morbidity and female gender were predictors of endocrine toxicity. There was no association between endocrine dysfunction and patient outcome. However, when all toxicities (i.e., endocrine and non endocrine) were considered, a significant association with progression-free survival and overall survival was found. CONCLUSIONS: Thyroid alterations are frequently observed in cancer patients treated with anti PD-1 drugs, particularly in women and in the presence of a previous endocrinopathy. We suggest that regular thyroid assessment should be performed in these patients, especially in the first months of therapy. Finally, the onset of side effects, related to anti PD-1 agents, appears to be associated with a better outcome. Springer US 2021-05-25 2021 /pmc/articles/PMC8440282/ /pubmed/34036513 http://dx.doi.org/10.1007/s12020-021-02750-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Rubino, Rossella
Marini, Andrea
Roviello, Giandomenico
Presotto, Elena Margherita
Desideri, Isacco
Ciardetti, Isabella
Brugia, Marco
Pimpinelli, Nicola
Antonuzzo, Lorenzo
Mini, Enrico
Livi, Lorenzo
Maggi, Mario
Peri, Alessandro
Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy
title Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy
title_full Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy
title_fullStr Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy
title_full_unstemmed Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy
title_short Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy
title_sort endocrine-related adverse events in a large series of cancer patients treated with anti-pd1 therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440282/
https://www.ncbi.nlm.nih.gov/pubmed/34036513
http://dx.doi.org/10.1007/s12020-021-02750-w
work_keys_str_mv AT rubinorossella endocrinerelatedadverseeventsinalargeseriesofcancerpatientstreatedwithantipd1therapy
AT mariniandrea endocrinerelatedadverseeventsinalargeseriesofcancerpatientstreatedwithantipd1therapy
AT roviellogiandomenico endocrinerelatedadverseeventsinalargeseriesofcancerpatientstreatedwithantipd1therapy
AT presottoelenamargherita endocrinerelatedadverseeventsinalargeseriesofcancerpatientstreatedwithantipd1therapy
AT desideriisacco endocrinerelatedadverseeventsinalargeseriesofcancerpatientstreatedwithantipd1therapy
AT ciardettiisabella endocrinerelatedadverseeventsinalargeseriesofcancerpatientstreatedwithantipd1therapy
AT brugiamarco endocrinerelatedadverseeventsinalargeseriesofcancerpatientstreatedwithantipd1therapy
AT pimpinellinicola endocrinerelatedadverseeventsinalargeseriesofcancerpatientstreatedwithantipd1therapy
AT antonuzzolorenzo endocrinerelatedadverseeventsinalargeseriesofcancerpatientstreatedwithantipd1therapy
AT minienrico endocrinerelatedadverseeventsinalargeseriesofcancerpatientstreatedwithantipd1therapy
AT livilorenzo endocrinerelatedadverseeventsinalargeseriesofcancerpatientstreatedwithantipd1therapy
AT maggimario endocrinerelatedadverseeventsinalargeseriesofcancerpatientstreatedwithantipd1therapy
AT perialessandro endocrinerelatedadverseeventsinalargeseriesofcancerpatientstreatedwithantipd1therapy